With the continuous advancement of biotechnology and medical field, cancer treatment has changed from the traditional “one-size-fits-all” model to a more refined and individualized plan. InnoModels Bio's iHuPDX in vivo pharmacodynamic model technology is leading the new trend of individualized precision medicine with its unique advantages.
The iHuPDX in vivo pharmacodynamic model is a xenotransplantation technology based on patients' individual tumor cells. By collecting cancer tissue samples from patients and transplanting them into animals such as mice, individualized transplant tumors are formed. The core of this technology is to establish a tumor model that is highly relevant to the actual situation of the patient, thus providing strong support for precision medicine.
A major feature of this technology is its high degree of individualization. Traditional tumor models are often based on standardized cell lines or tissue samples, which cannot fully reflect the uniqueness of a patient's tumor. The iHuPDX in vivo drug efficacy model, on the other hand, is derived directly from the patient's tumor cells, and is therefore able to more accurately simulate the biological characteristics of the patient's tumor, such as growth, metastasis and drug response. This individualized disease model not only helps doctors to understand the patient's tumor characteristics more comprehensively, but also provides an important basis for the development of personalized treatment plans.

In addition, the iHuPDX in vivo drug efficacy model also has significant advantages in drug response prediction. Due to the high degree of similarity between the model and the patient's tumor, researchers can test the response of different drugs to a specific patient's tumor on the model, thus predicting the efficacy and possible side effects of the drug in the patient's body. This predictive ability allows physicians to select the most appropriate drug combination and dosage for a patient prior to treatment, increasing the success rate of treatment and reducing unnecessary risks.
The iHuPDX in vivo efficacy model also excels in terms of technical stability and growth rate. With advanced primary cell inoculation technology, the model is able to achieve early and uniform growth, ensuring that efficacy experiments are conducted within the optimal window. At the same time, the homogenization of the same batch of samples is ensured by the cell suspension modeling method, resulting in a high degree of consistency in the growth rate and biological characteristics of the model. This stability not only ensures the reliability of the experimental results, but also reduces the experimental and time costs.
It is worth mentioning that InnoModels Biotechnology has also combined the iHuPDX in vivo efficacy model with the humanized model of the PBMC immune system to provide a more ideal model for tumor immunity research. This combination enables the model to simulate not only tumor growth and drug response, but also the interaction between the tumor and the immune system, providing a powerful tool for a deeper understanding of the tumor immune mechanism and the development of new immunotherapies.
In summary, the iHuPDX in vivo drug efficacy model of InnoModels Biotechnology has become an important support for individualized precision medicine with its high degree of individualization, accurate drug response prediction and stable and reliable growth characteristics. In the future, with the continuous development and improvement of this technology, it is believed that it will play an even more important role in the field of cancer treatment, bringing hope and gospel to more patients.